摘要
目的探讨噻托溴铵联合布地奈德吸入治疗矽肺合并中重度慢性阻塞性肺疾病(COPD)的临床疗效。方法选自2014年1月至2016年1月江西省胸科医院诊治的矽肺合并中重度慢性阻塞性肺疾病患者120例,随机分成对照组和研究组(A、B、C)共四组,每组30例,对照组给予沙丁胺醇气雾剂按需吸入常规治疗。研究组分3组,在对照组基础上给予吸入布地奈德气雾剂(A组)、吸入噻托溴铵粉雾剂(B组)、吸入噻托溴铵粉雾剂和布地奈德气雾剂(C组)进行治疗。对四组患者的血气分析、肺功能及呼吸困难评分变化进行分析。结果经过3个月的治疗后,C组PaO_2值明显高于A、B组和对照组的PaO_2值,C组PaCO_2值明显低于A、B组和对照组的PaCO_2值;C组SaO_2值高于A组、B组和对照组的SaO_2值,差异具有统计学意义(P<0.05)。C组肺功能的相关指标FEV_1、FEV_1/预计值及FEV_1/FVC均高于A、B组、对照组的相应指标;呼吸困难的评分下降值高于A、B组、对照组的下降值,差异具有统计学意义(P<0.05)。结论治疗矽肺合并中重度慢性阻塞性肺疾病,噻托溴铵联合布地奈德能明显改善患者的肺功能、血气指标、症状和运动耐力,效果优于单药组和对照组,且单药中B组各项指标改善效果比较好,对照组各项指标改善效果比较差。
Objective To inhale Tiotropium Bromide powder mist joint budesonide in the treatment of silicosis merger moderately severe chronic obstructive pulmonary disease（COPD） analysis of the clinical curative effect. Methods randomly selected data from January 2014 to January 2016,the author on the Jiangxi thoracic hospital make a diagnosis and give treatment of silicosis merger relation between 120 patients with chronic obstructive pulmonary disease,randomly divided into control group and the group A,B,C,a total of four groups,30 cases in each group,The control group given routine salbutamol aerosol therapy treatment.Studies three groups of components,in the control group given on the basis of single suction inhaled budesonide aerosol（group A）,single suction and combined Tiotropium Bromide powder mist（group B） Tiotropium Bromide powder mist and budesonide aerosol treatment（group C）. Blood gas and lung function in patients with four groups and dyspnea score then observe the changes of sports endurance is analyzed. Results After three months of treatment,the PaO2 values in group C were significantly higher than those in group A,B and control group,and the PaCO2 values in group C were significantly lower than those in group A,B and control group. The SaO2 values in group C were higher than those in group A,B and control group,The difference was significant（P〈0.05）.The related indexes of pulmonary function in group C,FEV1,FEV1/expected value and FEV1/FVC were higher than those in group A,B and control group. The score of dyspnea was higher than that of group A,group B and control group,The difference was significant（P〈0.05）. Conclusion treatment of silicosis with moderately severe chronic obstructive pulmonary disease,Tiotropium bromide joint budesonide can obviously improve the symptoms of patients with pulmonary function,blood gas index,and exercise endurance,the effect is better than the single drug group and the control group,and single drug group B to improve the effect is better,the indicat
作者
李赞华
刘晓俊
陈艳玲
刘国华
LI Zhanhua LIU Xiaojun CHEN Yanling et al.(Department of Respiratory, Jiangxi Provincial Chest Hospital,Nanchang, 330006, Chin Yugan County Hospital,Jiangxi Yugan, 335100, China.)
出处
《江西医药》
CAS
2017年第4期283-285,289,共4页
Jiangxi Medical Journal
基金
江西省卫生计生委科技计划(20151146)
